Kentucky HB153 prohibits certain boards from restricting buprenorphine and other medications for substance use disorder.
Kentucky HB153 declares an emergency and prohibits the Kentucky Board of Dentistry, Board of Nursing, Board of Medical Licensure, and Board of Pharmacy from enacting regulations that restrict or limit the prescribing, dispensing, or administering of buprenorphine-mono-product, buprenorphine-combined-with-naloxone, or any other Schedule III, IV, or V medication approved by the FDA for treating substance use disorder. The bill also nullifies specific administrative regulations and any amendments that are identical or substantially the same. This Act takes effect upon its passage and approval.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.